Information  X 
Enter a valid email address

Antisoma plc (SRC)

  Print      Mail a friend       Annual reports

Wednesday 02 May, 2007

Antisoma plc

Notice of EGM

London, UK: 2 May 2007 - Cancer drug developer Antisoma plc  (LSE:
ASM; USOTC: ATSMY) today announces that it will convene an
Extraordinary General Meeting of shareholders at the offices of CMS
Cameron McKenna, Mitre House, 160 Aldersgate Street, London, EC1A 4DD
on Friday 25 May 2007 at 11.00am. The Notice of the Extraordinary
General Meeting (including copies of the resolutions to be proposed
at the meeting) has been sent to shareholders and is available on the
Company's website,  A copy will shortly be
available for inspection at the Document Viewing facility.

Raymond Spencer
+44 (0)20 8799 8200
Chief Financial Officer
Antisoma plc

Notes for Editors:

Background on Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that
develops novel products for the treatment of cancer. Antisoma fills
its development pipeline by acquiring promising new product
candidates from internationally recognised academic or cancer
research institutions. Its core activity is the preclinical and
clinical development of these drug candidates. Please visit for further information about Antisoma.